Overview

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2027-01-21

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Bortezomib
Dexamethasone
Pomalidomide